Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

AGC Biologics A/S

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   2.2% 2.4% 1.9% 1.1% 1.1% 1.4% 9.3% 9.2%   Credit score (0-100)   68 65 70 82 83 77 26 27   Credit rating   BBB BBB A A A A BB BB   Credit limit (mDKK)   0.0 0.0 0.2 45.9 44.4 5.4 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1.0 Income statement (mDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   693 996 1,455 2,185 2,518 2,093 2,093 2,093   Gross profit   162 257 452 832 937 501 0.0 0.0   EBITDA   119 204 371 733 793 352 0.0 0.0   EBIT   119 204 371 733 793 352 0.0 0.0   Pre-tax profit (PTP)   124.0 198.0 357.0 734.1 768.5 316.0 0.0 0.0   Net earnings   96.0 154.0 279.0 571.7 598.9 243.9 0.0 0.0   Pre-tax profit without non-rec. items   119 204 371 734 766 316 0.0 0.0     See the entire income statement 1.0 Balance sheet (mDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 985 1,863 2,386 0.0 0.0   Shareholders equity total   317 215 340 634 661 307 264 264   Interest-bearing liabilities   0.0 0.0 0.0 265 35.3 1,076 0.0 0.0   Balance sheet total (assets)   635 1,182 2,348 3,141 3,357 3,624 264 264   Net Debt   0.0 0.0 -836 -212 -184 1,066 -264 -264     See the entire balance sheet 1.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   693 996 1,455 2,185 2,518 2,093 2,093 2,093   Net sales growth   7.7% 43.7% 46.1% 50.2% 15.2% -16.9% 0.0% 0.0%   Gross profit   162 257 452 832 937 501 0.0 0.0   Gross profit growth   3.3% 58.6% 75.9% 84.0% 12.6% -46.5% -100.0% 0.0%   Employees   312 377 441 730 894 956 0 0   Employee growth %   3.0% 20.8% 17.0% 65.5% 22.5% 6.9% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   635 1,182 2,348 3,141 3,357 3,624 264 264   Balance sheet change%   26.6% 86.1% 98.6% 33.8% 6.9% 7.9% -92.7% 0.0%   Added value   119.0 204.0 371.0 733.0 793.5 352.2 0.0 0.0   Added value %   17.2% 20.5% 25.5% 33.5% 31.5% 16.8% 0.0% 0.0%   Investments   -212 0 0 1,008 875 518 -2,401 0   Net sales trend   2.0 3.0 4.0 5.0 5.0 -1.0 0.0 0.0   EBIT trend   3.0 4.0 5.0 5.0 5.0 5.0 0.0 0.0   1.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   17.2% 20.5% 25.5% 33.5% 31.5% 16.8% 0.0% 0.0%   EBIT %   17.2% 20.5% 25.5% 33.5% 31.5% 16.8% 0.0% 0.0%   EBIT to gross profit (%)   73.5% 79.4% 82.1% 88.1% 84.7% 70.3% 0.0% 0.0%   Net Earnings %   13.9% 15.5% 19.2% 26.2% 23.8% 11.7% 0.0% 0.0%   Profit before depreciation and extraordinary items %   13.9% 15.5% 19.2% 26.2% 23.8% 11.7% 0.0% 0.0%   Pre tax profit less extraordinaries %   17.2% 20.5% 25.5% 33.6% 30.4% 15.1% 0.0% 0.0%   ROA %   20.9% 22.5% 21.0% 27.0% 24.4% 10.3% 0.0% 0.0%   ROI %   25.4% 22.5% 21.0% 40.8% 59.6% 21.4% 0.0% 0.0%   ROE %   31.6% 57.9% 100.5% 117.4% 92.5% 50.3% 0.0% 0.0%   1.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   100.0% 100.0% 100.0% 33.8% 32.7% 49.8% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 103.9% 104.3% 157.3% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% -57.5% 82.1% 95.6% 156.9% -12.6% -12.6%   Net int. bear. debt to EBITDA, %   0.0% 0.0% -225.4% -28.9% -23.2% 302.8% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 41.8% 5.3% 349.9% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 5.8% 18.2% 7.5% 0.0% 0.0%   1.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.0 0.0 0.0 2.7 1.6 0.7 0.0 0.0   Current Ratio   0.0 0.0 0.0 1.1 0.7 0.5 0.0 0.0   Cash and cash equivalent   0.0 0.0 836.4 476.9 219.4 9.2 0.0 0.0   1.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 62.8 82.3 68.4 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 57.5% 96.7% 57.6% 57.3% 12.6% 12.6%   Net working capital   0.0 0.0 836.4 229.8 -487.8 -981.9 0.0 0.0   Net working capital %   0.0% 0.0% 57.5% 10.5% -19.4% -46.9% 0.0% 0.0%   1.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   2 3 3 3 3 2 0 0   Added value / employee   0 1 1 1 1 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 1 1 1 1 0 0 0   EBIT / employee   0 1 1 1 1 0 0 0   Net earnings / employee   0 0 1 1 1 0 0 0